Solid forms comprising 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, and a coformer, compositions and methods of use thereof
Disclosed is the compound 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one (formula (I)). Also disclosed are solid forms with coformers, in particular benzoic acid, fumaic acid, gentisic acid, nicotinamide, succinic acid or mandelic acid. Further disclosed are crystal forms with x-ray powder diffraction peaks (XRPD) listed in the specification. The compounds are useful mTOR inhibitors
